A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD

NCT01376245 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

646

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: fluticasone furoate/vilanterol
DRUG: Placebo

Sponsor

GlaxoSmithKline